UPDATE: uniQure Says Will Now Conduct As Sole Primary Endpoint For Hemophilia B Candidate 'a non-inferiority analysis of annualized bleeding rates (ABR) at 78 weeks after the administration (approximately 52-weeks after steady-state is achieved)'